Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05483283 · ClinicalTrials.gov registry record · NA

Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care

A NA study of Breast Cancer, sponsored by University of Illinois at Chicago.

Recruiting
Registry status
NA
Development phase
600
Enrollment target
1
Study location

NCT05483283 is a NA study of Breast Cancer that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 600 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05483283, a NA study of Breast Cancer, is actively recruiting participants, sponsored by University of Illinois at Chicago.

RECRUITING
Registry status
NA
Development phase
600 participants
Enrollment target
1
Study location

Study Summary

The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions with the study team across 3 consecutive weeks

Conditions Studied

Interventions

  • OTHER SOC
  • OTHER Empowerment and Navigation

Study Locations (1)

Illinois

  • University of Illinois - Chicago

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2023-01-18
Est. Completion 2027-09
Phase NA

Sponsor

University of Illinois at Chicago

430 total trials

What the Registry Record Tells You About NCT05483283

The ClinicalTrials.gov registry entry for NCT05483283 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (79% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which SOC is the first listed.

NCT05483283 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05483283 about?

NCT05483283 is a clinical study titled "Empowering Vulnerable and Resilient Latinas to Obtain Breast Cancer Care". The investigator and study staff will identify, recruit and randomize Latina participants with elevated genetic and Social Determinants of Heath (SDH) risks. Within 1 week of enrollment, all Latina Aim 1 participants in both study arms will engage in three 30-minute, individual, phone-based sessions...

What is the current status of trial NCT05483283?

This trial is currently recruiting. It is a NA study. The enrollment target is 600 participants. The study started on 2023-01-18. Estimated completion is 2027-09.

What conditions does trial NCT05483283 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05483283?

The interventions under investigation include: SOC (OTHER), Empowerment and Navigation (OTHER).

Who is sponsoring clinical trial NCT05483283?

This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05483283 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.